Francesco Mattia Mancuso has a total of 307 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiomics Signature Reveals Network Regulatory Mechanisms in a CRC Continuum

    by Juan Carlos Higareda-Almaraz, Francesco Mattia Mancuso, Pol Canal-Noguer, Kristi Kruusmaa, Arianna Bertossi

    Sporadic colorectal cancer (CRC), the third leading cause of cancer-related death globally, arises through a continuum from normal tissue to adenomas, progressing from low-grade (LGD) to high-grade dysplasia (HGD); yet, the early epigenetic drivers of this transition remain unclear. To investigate these events, we profiled LGD and HGD adenomas using EM-seq, and identified a consensus differential methylation signature (DMS) of 626 regions through two independent bioinformatics pipelines. This signature effectively distinguished LGD from HGD in both tissue and plasma-derived cell-free DNA (cfDNA), highlighting specific methylation patterns. Functional annotation indicated enrichment for regulatory elements associated with transcription factor activity and cell signaling. Applying the DMS to the TCGA CRC dataset revealed three tumor subtypes with increasing hypermethylation and one normal cluster. The most hypermethylated subtype exhibited poor survival, high mutation burden, and disrupted transcriptional networks. While overlapping with classical CpG Island Methylator Phenotype (CIMP) categories, the DMS captured a broader spectrum of methylation alterations. These findings suggest that the DMS captures functionally relevant, antecedent epigenetic alterations in CRC progression, enabling the robust stratification of dysplasia severity and tumor subtypes. This signature holds promise for enhancing preclinical detection and molecular classification, and warrants further evaluation in larger prospective cohorts.


  • Open Access

    Multiomics Signature Reveals Network Regulatory Mechanisms in CRC Continuum

    by Juan Carlos Higareda-Almaraz, Francesco Mattia Mancuso, Pol Canal-Noguer, Kristi Kruusmaa, Arianna Bertossi

    Colorectal cancer (CRC), the third leading cause of cancer-related death globally, sporadic CRC arises through a continuum from normal tissue to adenomas, progressing from low-grade (LGD) to high-grade dysplasia (HGD), yet early epigenetic drivers of this transition remain unclear. To investigate these early events, we profiled LGD and HGD adenomas using EM-seq and identified a consensus Differential Methylation Signature (DMS) of 626 regions through two independent bioinformatics pipelines. This signature effectively distinguished LGD from HGD in both tissue and plasma-derived cell-free DNA (cfDNA), highlighting specific methylation patterns. Functional annotation indicated enrichment for regulatory elements associated with transcription factor activity and cell signaling. Applying the DMS to TCGA CRC dataset revealed three tumor subtypes with increasing hypermethylation and one normal cluster. The most hypermethylated subtype exhibited poor survival, high mutation burden, and disrupted transcriptional networks. While overlapping with classical CpG Island Methylator Phenotype (CIMP) categories, the DMS captured a broader spectrum of methylation alterations. These findings suggest that the DMS reflects early, functionally relevant epigenetic changes in CRC progression, enabling robust stratification of dysplasia severity and tumor subtypes. The DMS has the potential to improve early detection and molecular classification, warranting further validation in larger, prospective cohorts.


  • Open Access

    Colorectal Adenoma Subtypes Exhibit Signature Molecular Profiles: Unique Insights into the Microenvironment of Advanced Precancerous Lesions for Early Detection Applications

    by Francesco Mattia Mancuso, Juan Carlos Higareda-Almaraz, Pol Canal-Noguer, Arianna Bertossi, Alexandre Perera-Lluna, Michael Herbert Alexander Roehrl, Kristi Kruusmaa

    Background: Colorectal cancer (CRC) is characterized by the uncontrolled growth of malignant colonic or rectal crypt epithelium. About 85% of CRCs evolve through a stepwise progression from advanced precancerous adenoma lesions. A better understanding of the evolution from adenoma to carcinoma can provide a window of opportunity not only for early detection and therapeutic intervention but potentially also for cancer prevention strategies. Methods: This study investigates the heterogeneous methylation, copy-number alteration (CNA), and mutation signals of histological adenoma subtypes in the context of progression from normal colon to advanced precancerous lesions (APLs) and early-stage CRC. Results: Differential methylation analysis revealed 2321 significantly altered regions among APLs: 137 hypermethylated regions in serrated vs. tubular, 2093 in serrated vs. tubulovillous, and 91 in tubular vs. tubulovillous adenoma subtypes. The most differentiating pathways for serrated adenomas belonged to cAMP signaling and the regulation of pluripotency of stem cells, while regions separating tubular and tubulovillous subtypes were enriched for WNT signaling. CNA events were mostly present in tubular or tubulovillous adenomas, with the most frequent signals being seen in chromosomes 7, 12, 19, and 20. In contrast, early-stage CRC exhibited signals in chromosomes 7, 8, and 20, indicating different processes between APL and early-stage CRC. Mutations reinforce subtype-level differences, showing specific alterations in each subtype. Conclusions: These findings are especially important for developing early detection or cancer prevention tests trying to capture adenoma signatures.


  • Open Access

    Colorectal Adenoma Subtypes Exhibit Signature Molecular Profiles: Unique Insights into the Microenvironment of Advanced Precancerous Lesions for Early Detection Applications

    by Francesco Mattia Mancuso, Juan Carlos Higareda-Almaraz, Pol Canal-Noguer, Arianna Bertossi, Alexandre Perera-Lluna, Michael Herbert Alexander Roehrl, Kristi Kruusmaa

    Background: Colorectal cancer (CRC) is characterized by uncontrolled growth of malignant colonic or rectal crypt epithelium. About 85% of CRCs evolve through a stepwise progression from dysplastic colorectal adenomas. Better understanding of the evolution from adenoma to carcinoma can provide a window of opportunity not only for early detection and therapeutic intervention but potentially also for cancer prevention strategies. Methods: This study investigates the heterogeneous methylation, copy number alteration (CNA), and mutation signals of histological adenoma subtypes in the context of progression from normal colon to Advanced Precancerous Lesions (APLs) and early-stage CRC. Results: Differential methylation analysis revealed 2,321 significantly altered regions among APLs: 137 hypermethylated regions between serrated vs. tubular, 2,093 between serrated vs. tubulovillous, and 91 between tubular vs. tubulovillous adenoma subtypes, respectively. The most differentiating pathways for serrated adenomas belonged to cAMP signaling and regulation of pluripotency of stem cells, while regions separating tubular and tubulovillous subtypes were enriched for WNT signaling. CNA events were mostly present in tubular or tubulovillous adenomas, with the most frequent signals seen in chromosomes 7, 12, 19 and 20. In contrast, early-stage CRC exhibited signals in chromosomes 7, 8 and 20, indicating different processes between APL and early-stage CRC. Mutations reinforce subtype level differences, showing specific alterations in each subtype. Conclusions: These findings are especially important for developing early detection or cancer prevention tests trying to capture adenoma signatures.

  • Open Access

    Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

    by Jaume Capdevila, Ignacio Matos, Francesco M. Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Jorge Hernando, et al.

    Several biomarkers have been suggested to have prognostic value in differentiated thyroid carcinomas (DTC) with no validation in the refractory setting, including all tumor subtypes. We aim to correlate RNA expression profiles with survival based on patients included in the DECISION trial. We obtained 247 samples from the 417 patients included in the DECISION study and performed RNAseq analysis (77 million paired-end reads for each sample on HiSeq2000). After quality control, 125 samples were included in the secondary analysis and mapped against the human reference genome (GRCh38) with STAR (v2.5.1b) using ENCODE parameter. Survival analysis was calculated using the Kaplan–Meier method and log-rank test was used for statistical comparison. In this post hoc analysis, we identified three groups of tumors based on their gene expression profile: BRAF-like, RAS-like, and non-BRAF-non-RAS-like (NoBRaL). No significant correlation with sorafenib responders was observed. However, we identified a statistically significant correlation between the RNA-expression profiles and progression-free survival. The BRAF-like profile had a significantly better outcome compared with RAS-like and NoBRaL (11.8, 6.2, and 5.5 months, respectively) [HR: 0.31, 95% confidence interval (CI), 0.17–0.60; P < 0.001 and HR: 0.36 (95% CI, 0.21–0.63); P < 0.001] and HR: 0.36 (95% CI, 0.21–0.63; P < 0.001) and maintained significance as an independent prognostic factor for overall survival in the multivariate analysis for papillary thyroid cancers. To our knowledge, this is the first comprehensive RNA-seq analysis of all histologic subtypes of DTC. The RNA expression profiles identified may suggest a new prognostic parameter to be considered before recommendation of systemic therapies or the design of stratification factors for future clinical trials.

  • Open Access

    Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

    by Jaume Capdevila, Ignacio Matos, Francesco M. Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Jorge Hernando, et al.

    Table 1: samples included in the RNAseq analysis Figure 1: consort flow diagram Table 2: Comparison of patients' characteristics of the subset of patients included in the RNA-seq analysis and patients recruited in the DECISION study Figure 2: Progression-free survival of the subgroup of patients included in the RNA-seq analysis. Table 3: Pathways_GO_analysis Figure 3: Kaplan-Meyer curves of the three RNA expression groups regarding treatment group in DECISION trial. Figure 4: A,B,C: PFS in papillary, follicular and poorly differentiated histologies, respectively; D,E,F: OS in papillary, follicular and poorly differentiated histologies, respectively Figure 5: Overall survival (OS) analysis based on RNA expression profile from TCGA data of papillary thyroid cancer (Cell, 2014) Figure 6: Analyses based on 121 angiogenesisrelated genes

  • Open Access

    Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

    by Jaume Capdevila, Ignacio Matos, Francesco M. Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Jorge Hernando, et al.

    Table 1: samples included in the RNAseq analysis Figure 1: consort flow diagram Table 2: Comparison of patients' characteristics of the subset of patients included in the RNA-seq analysis and patients recruited in the DECISION study Figure 2: Progression-free survival of the subgroup of patients included in the RNA-seq analysis. Table 3: Pathways_GO_analysis Figure 3: Kaplan-Meyer curves of the three RNA expression groups regarding treatment group in DECISION trial. Figure 4: A,B,C: PFS in papillary, follicular and poorly differentiated histologies, respectively; D,E,F: OS in papillary, follicular and poorly differentiated histologies, respectively Figure 5: Overall survival (OS) analysis based on RNA expression profile from TCGA data of papillary thyroid cancer (Cell, 2014) Figure 6: Analyses based on 121 angiogenesisrelated genes

  • Open Access

    Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial

    by Jaume Capdevila, Ignacio Matos, Francesco M. Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Jorge Hernando, et al.

    Several biomarkers have been suggested to have prognostic value in differentiated thyroid carcinomas (DTC) with no validation in the refractory setting, including all tumor subtypes. We aim to correlate RNA expression profiles with survival based on patients included in the DECISION trial. We obtained 247 samples from the 417 patients included in the DECISION study and performed RNAseq analysis (77 million paired-end reads for each sample on HiSeq2000). After quality control, 125 samples were included in the secondary analysis and mapped against the human reference genome (GRCh38) with STAR (v2.5.1b) using ENCODE parameter. Survival analysis was calculated using the Kaplan–Meier method and log-rank test was used for statistical comparison. In this post hoc analysis, we identified three groups of tumors based on their gene expression profile: BRAF-like, RAS-like, and non-BRAF-non-RAS-like (NoBRaL). No significant correlation with sorafenib responders was observed. However, we identified a statistically significant correlation between the RNA-expression profiles and progression-free survival. The BRAF-like profile had a significantly better outcome compared with RAS-like and NoBRaL (11.8, 6.2, and 5.5 months, respectively) [HR: 0.31, 95% confidence interval (CI), 0.17–0.60; P < 0.001 and HR: 0.36 (95% CI, 0.21–0.63); P < 0.001] and HR: 0.36 (95% CI, 0.21–0.63; P < 0.001) and maintained significance as an independent prognostic factor for overall survival in the multivariate analysis for papillary thyroid cancers. To our knowledge, this is the first comprehensive RNA-seq analysis of all histologic subtypes of DTC. The RNA expression profiles identified may suggest a new prognostic parameter to be considered before recommendation of systemic therapies or the design of stratification factors for future clinical trials.

  • Open Access

    Supplementary Figure 1 from Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

    by Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jimenez-Fonseca, Carlos Lopez Lopez, et al.

  • Open Access

    Supplementary Figure Legends from Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

    by Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jimenez-Fonseca, Carlos Lopez Lopez, et al.